Thursday, 22 June 2017

In-Depth Review on Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2017

Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.
Alpha-7 integrin is a protein encoded by the ITGA7 gene. It induces changes in the shape and mobility of myoblasts, and facilitates their localization at laminin-rich sites of secondary fiber formation. It is involved in the maintenance of the myofibers cytoarchitecture as well as for their anchorage, viability and functional integrity.
This report outlays comprehensive information on the Integrin Alpha 7 (ITGA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 4 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders and Genetic Disorders which include indications Muscular Dystrophy and Duchenne Muscular Dystrophy.
- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 7 (ITGA7)
- The report reviews Integrin Alpha 7 (ITGA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Integrin Alpha 7 (ITGA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Integrin Alpha 7 (ITGA7) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Integrin Alpha 7 (ITGA7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Alpha 7 (ITGA7) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Strykagen Corp
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research


Post a Comment

Subscribe to Post Comments [Atom]

<< Home